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While it is apparent that rare variation can play an important role in the genetic architecture of autism spec-
trum disorders (ASDs), the contribution of common variation to the risk of developing ASD is less clear. To
produce a more comprehensive picture, we report Stage 2 of the Autism Genome Project genome-wide asso-
ciation study, adding 1301 ASD families and bringing the total to 2705 families analysed (Stages 1 and 2). In
addition to evaluating the association of individual single nucleotide polymorphisms (SNPs), we also sought
evidence that common variants, en masse, might affect the risk. Despite genotyping over a million SNPs cov-
ering the genome, no single SNP shows significant association with ASD or selected phenotypes at a
genome-wide level. The SNP that achieves the smallest P-value from secondary analyses is rs1718101. It
falls in CNTNAP2, a gene previously implicated in susceptibility for ASD. This SNP also shows modest asso-
ciation with age of word/phrase acquisition in ASD subjects, of interest because features of language devel-
opment are also associated with other variation in CNTNAP2. In contrast, allele scores derived from the
transmission of common alleles to Stage 1 cases significantly predict case status in the independent
Stage 2 sample. Despite being significant, the variance explained by these allele scores was small (Vm<
1%). Based on results from individual SNPs and their en masse effect on risk, as inferred from the allele
score results, it is reasonable to conclude that common variants affect the risk for ASD but their individual
effects are modest.
INTRODUCTION
Genetic analyses over the past two decades have connected a
plethora of rare mutations with the risk for autism spectrum
disorder (ASD) (1–9). The rate of discovery has accelerated
remarkably with the use of genome-wide screening tools
capable of identifying sub-microscopic structural DNA vari-
ation (10). Many of the identified risk variants occur de
novo and implicate many genes. From the distribution of de
novo copy number variants (CNVs) in affected individuals
and their unaffected siblings, Sanders et al. (11) conclude
that there are hundreds of ASD risk loci in the human
genome. This magnitude for risk genes is also supported by
the distribution of de novo sequence events in ASD probands
(12–15). Indeed, over the past year evidence supporting rare
variation affecting risk, both de novo and inherited, continues
to accumulate through both copy number and sequence-based
studies (11–20).
In contrast, genome-wide evidence for common variation
affecting the risk for ASD is limited. In a recent study by
this group, the Autism Genome Project (AGP), we reported
on a genome-wide association study (GWAS) of almost
1400 strictly defined ASD families genotyped for one
million single nucleotide polymorphisms (SNPs) (21) (herein
referred to as Stage 1). We performed four primary association
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analyses based on ancestry and clinical thresholds and identi-
fied a single, marginally significant association for SNP
rs4141463 located within MACROD2. Other large GWAS
also highlighted significant associations at single loci,
namely SNPs at 5p14.1 (22) and 5p15.2 (23). In our previous
Stage 1 GWAS, we did not find evidence to support either of
these earlier associations (21). Likewise, a subsequent study in
an independent collection of 1170 individuals of European an-
cestry with ASD and 35307 non-ASD controls finds no
support for the MACROD2 marker rs4141463 (24).
The objective of the AGP has been to characterize the
genetic architecture of ASD, and therefore we sought to deter-
mine whether both common variants and rare CNVs account
for risk and, if so, by how much. Thus far, we can conclude
that rare variation plays a substantial role (9,25), complement-
ing many other studies (26,27). What we can say about
common variation is less definitive. Based on the analysis of
published GWAS, Devlin et al. (28) concluded that common
genomic variants having a substantial impact on risk (relative
risk .1.5) do not exist; there could be a small number of
common risk variants, as yet unidentified, having an inter-
mediate impact on risk (relative risk 1.2–1.5); yet there
could be many common variants of modest impact (relative
risk ,1.2). To consistently and reliably detect common var-
iants of modest effect will require samples in the tens of thou-
sands (29).
To produce a more comprehensive picture of how common
variants affect the risk for ASD, we report the second stage of
the AGP GWAS, amounting to an additional 1301 ASD fam-
ilies as a combined mega-analysis of Stage 1 and Stage 2. In
addition to the single SNP analyses, we use the two-stage
design to evaluate the SNPs, en masse, for evidence that a
large number of common variants exert at least weak effects
on risk. The allele-score method, as previously described by
Purcell et al. (30), calculates an accumulated score for each in-
dividual based on the presence and count of associated alleles
(for family-based association, the count is the over-transmitted
allele). With their data, the International Schizophrenia Con-
sortium found that those common variants assessed (M)
could explain up to 3.18% of the additive genetic variance
(VM) for schizophrenia (30). To estimate how much of the
variance for ASD can be explained by common variants, the
allele score derived from the Stage 1 data (21) was used to
predict case status in the Stage 2 data and calculate the VM.
RESULTS
Properties of the Stage 1 sample are reported elsewhere (21).
When combined with the Stage 2 data, we report the largest
family-based sample of ASD to date (Table 1). Ancestry ana-
lysis, estimated from numerous genetic markers by using
standard techniques (31–33) and mapped back onto European
recruitment sites to anchor the common ancestry of subjects,
showed that 94.9% of the probands are of European ancestry
(Supplementary Material, Fig. S1). The primary analyses
target four overlapping data sets, based on diagnosis (spectrum
versus strict) and ancestry (only European versus any ances-
try). Of these four samples, the most inclusive allows for a
spectrum diagnosis for subjects of any ancestry (Table 1),
whereas the least inclusive allows for only a strict diagnosis
of autism for subjects of European ancestry (see Supplemen-
tary Material, Fig. S2 for experimental design).
Association analyses of these four classes do not identify
any single SNP to be significantly associated with autism as
judged by an accepted threshold for genome-wide signifi-
cance, P , 5 × 1028. Instead the distributions of test statistics
are consistent with that expected by chance (Supplementary
Material, Fig. S3). Only four genomic regions show associ-
ation signals at P , 1026, two falling in genes (Table 2; Sup-
plementary Material, Figs S4 and 5). When we evaluated the
corresponding Stage 2 results with SNPs highlighted by our
Stage 1 study (21), only one shows evidence of a modest as-
sociation, namely rs4150167, which is a non-synonymous
variant in TAF1C (Spectrum, All ancestries; rs4150167-A;
Stage 1 OR ¼ 0.37, P ¼ 7.87 × 1027; Stage 2 OR ¼ 0.65, P
¼ 0.014).
Exploratory analyses also produce no significant findings
after adjusting for multiple testing (Table 3). A detailed
summary of these findings is given in the Supplementary Ma-
terial, Table S1; Fig. S5). Results from Stage 2 analysis alone
are presented in Supplementary Material, Table S2, but are not
discussed in the main manuscript. Of the promising results
from other GWAS studies (22,23,34), only rs1328244
(13q33.3) and rs6646569 (Xq24) described by Wang et al.
(22) garner support from the combined AGP sample, although
it is important to bear in mind that the studies overlap some-
what in samples/families and thus correlated statistics are
expected (Table 4).
Under the hypothesis that individual common variants exert
only a limited effect on risk and that many such variants are
present and exert these effects independently, we would
expect these effects to be detectable in an analysis of
common variants en masse. To address this question, allele
scores were generated for all AGP probands based on the
four Stage 1 primary analyses with the goal of determining
whether the score derived from the Stage 1 results predicted
the Stage 2 case versus control status. Allele scores based
on markers associated at 10 significance thresholds ranging
from P, 0.5 to P, 0.00001 were evaluated. Used as a posi-
tive control for the method, the Stage 1 scores showed high to
perfect predictive value for case status in the Stage 1 subjects
(data not shown). When examined against Stage 2 individuals,
the Stage 1 scores were significant predictors of case status
(Fig. 1) and thus explain a significant portion of variance in
case and control status of Stage 2 samples. In general, the vari-
ance explained increases with an increased number of markers
in the model. Still the markers explain only a small proportion
of the variance—always ,1%, with the greatest signal
observed in the smallest yet most homogeneous group,
namely European ancestry individuals with a Strict diagnosis
of autism (Vm ¼ 0.78%; Empirical P , 0.001). Analyses
stratifying by quintile of minor allele frequency showed that
most of the variance explained accrues to the quintile 0.2–
0.3 (Supplementary Material, Fig. S6). Although these
results were noisy (Supplementary Material, Fig. S6), they
suggest that many common variants affect risk.
Importantly the allele-score analysis assumes that the distri-
bution of liability for pseudo controls is similar to that of the
general population. Various factors could skew this
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distribution and thus bias downwards the estimated Vm, a
notable one being an excess of multiplex families relative to
population frequencies (35,36). Multiplex families comprise
at least 33% of the families studied here (47.5% simplex,
19.5% unknown), and thus could substantially diminish the
estimated Vm. In addition, as pointed out by Ripke et al.
(37), the use of a larger sample size to develop the predictor
(i.e. model from the Stage 1 sample) should produce a more
accurate allele score and thus increase the amount of variance
in the Stage 2 case and control status explained.
DISCUSSION
For this report the AGP genotyped 1301 additional families for
almost one million SNPs, bringing the total analysed herein to
2678 families. From this large data set, we observed no
genome-wide significant association with specific common
variants. Four independent signals in the primary analyses
yielded uncorrected P-values ,1 × 1026 and 23 independent
signals in the exploratory analyses crossed this threshold
(Tables 2 and 3). Some of these SNPs fall in intriguing
genes, including TAF1C from the primary analyses and
CNTNAP2 from the exploratory analyses. TAF1C encodes
the TATA box-binding protein-associated factor RNA poly-
merase I subunit C. We previously highlighted and discussed
TAF1C and the corresponding SNP (rs4150167) (21). Of interest
is that the common allele for rs4150167 was over-transmitted
and is represented on roughly 98% of the chromosomes. The
same pattern, although not as extreme, is present in the
Stage 2 sample and again cannot be traced to a genotyping
error (Supplementary Material, Fig. S7). If this were a true
causal effect, it suggests that the minor allele at rs4150167
is somehow protective. The protective allele results in a
non-synonymous glycine to arginine change at amino acid
position 523 and has also been implicated in alternate splicing
(38), both of which offer a starting point for investigation of
the impact of this variation on gene function. On the other
hand the association should be viewed cautiously because
the power of this study to detect a protective effect is small.
Statistically, therefore, the posterior probability that this obser-
vation is a false positive is large.
The strongest uncorrected association observed across all
analyses was for rs1718101 in European individuals with
Table 1. The sample size for specific family-based analyses
Analysis Stage 2 Combined Stages 1 and 2
No. of families Cases per familya No. of families Cases per family
1 2 3 1 2 3
Spectrum 1301 1289 11 1 2705 2678 26 1
Strict 785 782 3 0 1673 1667 6 0
Spectrum/European 1108 1096 11 1 2384 2359 24 1
Strict/European 660 657 3 0 1458 1452 6 0
Verbal 951 947 3 1 1884 1868 15 1
Non-verbal 333 331 2 0 799 796 3 0
Verbal/European 830 826 3 1 1686 1672 13 1
Non-verbal/European 266 264 2 0 682 679 3 0
Upper IQ 594 594 0 0 1191 1187 4 0
Lower IQ 307 307 0 0 672 670 2 0
Upper IQ/European 528 528 0 0 1067 1064 3 0
Lower IQ/European 221 221 0 0 551 549 2 0
Word 1068 1061 6 1 2241 2222 18 1
Phrase 946 941 4 1 1893 1877 15 1
aAll families were required to have maternal and paternal genotypes. In addition, the sample size listed here are the families and samples that passed quality control
criteria.
Table 2. Top hits from the primary analyses in the combined AGP GWA sample
Chr Position SNP Gene Diagnosis Ancestry P OR OR1 OR2
2 205794415 rs4675502 PARD3B Strict All 4.340e-07 1.28 (1.16–1.41) 1.29 1.27
5 162016095 rs7711337 NONE Spectrum All 8.254e-07 0.82 (0.76–0.89) 0.83 0.81
8 72724295 rs7834018 NONE Strict European 7.538e-07 0.64 (0.53–0.77) 0.63 0.65
16 82771184 rs4150167 TAF1C Spectrum All 2.910e-07 0.51 (0.39–0.66) 0.37 0.65
The SNPs listed are restricted to top associated SNP if more than one SNP within a linkage disequilibrium (LD) block exists; for additional associated SNPs in LD
with the index SNP, see Supplementary Material. OR1, odds ratio from Stage 1 data; OR2, odds ratio for Stage 2 data; OR is the overall odds ratio (95% confidence
interval); P, the P-value for OR. The distribution of the association signals around these SNPs for these ancestral and diagnostic categories is shown in
Supplementary Material, Figure S4. Graphical representation of the association signal for these highlighted SNPs across stages and diagnostic groups is plotted in
Supplementary Material, Figure S5.
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higher IQ (P-value ¼ 7.8 × 1029; OR ¼ 2.13). This SNP is
not in substantial linkage disequilibrium (LD) with other gen-
otyped SNPs and thus no other SNP genotyped by this study
supports its association. Examination of the genotype intensity
plots, however, showed good quality clustering (Supplemen-
tary Material, Fig. S7). The SNP resides within CNTNAP2
(7q35), which encodes the Contactin-associated protein-like
2, a member of the neurexin-family thought to play a role in
axonal differentiation and guidance. CNTNAP2 is one of the
largest genes in the human genome encompassing 1.5% of
chromosome 7 and has previously been implicated in ASD,
in part because it resides within regions of suggestive
linkage (39). CNVs falling in other neurexin genes including
NRXN1 have been implicated in ASD (4,8,9,25,40,41). More
directly, rare variation in CNTNAP2, including CNVs, other
structural disruptions and deleterious sequence variation, has
been identified in subjects with autism, epilepsy, intellectual
disability, Pitt-Hopkins-like syndrome, schizophrenia and
Tourette syndrome (42–48), albeit with differing degrees of evi-
dence for effect on these traits. Although the most compelling
Table 3. The most associated SNPs from the secondary analyses in the combined sample
Chr Position SNP Gene Diagnosis/subgroup Inheritance P OR OR1 OR2
1 116327194 rs12726299 SLC22A15 Verba/Eurb Paternal 1.496e207 1.51 (1.29–1.76) 1.61 1.43
1 204764871 rs11118968 RASSF5 Spectc/All Maternal 2.452e207 0.44 (0.32–0.61) 0.43 0.45
2 230226476 rs6752370 DNER Strict/All Maternal 8.526e207 1.62 (1.33–1.96) 1.56 1.67
2 31000000 rs10205350 GALNT14 Nverbd/All Maternal 3.942e207 0.50 (0.38–0.66) 0.57 0.40
3 185006350 rs263035 YEATS2 Spect/All Paternal 2.258e207 1.39 (1.22–1.57) 1.29 1.49
4 147068744 rs12331851 ZNF827 Verb/Eur Paternal 6.081e207 0.38 (0.26–0.57) 0.49 0.28
5 2162900 rs6879627 NONE IQ+e/Eur Maternal 3.992e207 0.52 (0.40–0.67) 0.63 0.43
5 65575602 rs29456 NONE Strict/All Maternal 1.226e207 1.65 (1.37–1.99) 1.54 1.75
7 145753720 rs1718101 CNTNAP2 IQ+/Eur Additive 7.783e209 2.13 (1.63–2.80) 2.16 2.11
10 119652081 rs1936295 NONE Spect/Eur Maternal 6.636e207 1.69 (1.37–2.09) 1.70 1.66
10 55971935 rs1930165 PCDH15 IQ+/All Maternal 9.861e208 0.60 (0.50–0.73) 0.57 0.63
11 106363884 rs11211996 GUCY1A2 Nverb/Eur Paternal 4.287e207 2.11 (1.56–2.85) 1.67 3.00
11 113578084 rs3782000 ZBTB16 IQ+/All Additive 1.842e207 1.41 (1.24–1.61) 1.37 1.45
16 4941380 rs9635542 NONE Nverb/All Paternal 3.268e207 0.44 (0.32–0.61) 0.39 0.52
16 61230112 rs288604 NONE Spect/All Maternal 2.975e207 1.58 (1.32–1.88) 1.59 1.57
17 68575820 rs9302952 SLC39A11 Verb/All Maternal 4.039e207 1.64 (1.35–1.99) 1.77 1.54
18 34259508 rs932026 NONE IQ+/Eur Maternal 1.473e207 0.44 (0.32–0.60) 0.35 0.52
18 66531220 rs17083037 NONE IQ+/All Additive 1.368e207 0.47 (0.35–0.63) 0.51 0.43
18 7024945 rs600695 LAMA1 IQ+/All Paternal 3.578e207 1.61 (1.34–1.94) 1.58 1.64
20 14810971 rs6110458 MACROD2 Spect/All Maternal 1.806e207 1.46 (1.27–1.69) 1.56 1.39
20 14813155 rs14135 CR596518/MACROD2 Spect/All Maternal 1.778e207 1.49 (1.28–1.74) 1.61 1.40
20 14815421 rs1475531 CR596518/MACROD2 Strict/All Maternal 2.011e207 1.53 (1.30–1.79) 1.85 1.28
21 38787019 rs2836439 ERG IQ-f/Euro Paternal 6.638e207 0.42 (0.30–0.60) 0.39 0.47
SNPs listed are restricted to top associated SNP if more than one SNP within a linkage disequilibrium (LD) block exists; for additional associated SNPs in LD with
the index SNP, see Supplementary Material. Note that P-values are not corrected for multiple testing and none of the results reported here should be considered
significant. OR1, odds ratio from Stage 1 data; OR2, odds ratio for Stage 2 data; OR is the overall odds ratio (95% confidence interval); P, the P-value for OR.
aVerbal.
bEuropean.
cSpectrum.
dNon-verbal.
eHigher IQ.
fLower IQ.
Table 4. Top hits from regions previously implicated as autism susceptibility regions from non-AGP studies
Chr Position SNP Original P-value Reference P-value Best P (+10 kb)
5 9677904 rs10513025a 2.1 × 1027 (22) 0.546 rs41457; P ¼ 0.0569
5 26003459 rs4307059 2.1 × 10210 (21)b 0.2033 rs7732252; P ¼ 0.0915
13 108881898 rs1328244 8.2 × 1027 (21)b 0.0094 rs1328244; P ¼ 0.0094
14 39901753 rs7147817 2.7 × 1027 (21)b 0.5591 rs4903707; P ¼ 0.2756
16 19116069 rs9932538 1.9 × 1027 (21)b 0.2459 rs7188617; P ¼ 0.2028
X 4940800 rs11798405 9.0 × 1027 (21)b 0.5664 rs5961595; P ¼ 0.0406
X 32391976 rs5972577 2.7 × 1027 (21)b 0.695 rs6653872; P ¼ 0.1086
X 119133917 rs6646569 9.7 × 1027 (21)b 0.0022 rs6646569; P ¼ 0.0022
aUsed proxy rs2234235 which is in perfect or almost perfect LD with rs10513025.
bIn the Stage 1 sample reported in Anney et al. (21) 111 AGRE families overlapped with Wang et al. (22) or 8.1%; in the entire AGP sample the overlap is more
substantial, 858 spectrum subjects (analysed in a case–control setting) or 31%.
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evidence is for recessively inherited Pitt-Hopkins-like syndrome,
the other studies are more consistent with dominant or additive
effects. Common variants in CNTNAP2 have also been asso-
ciated with ASD (49–51) and specific-language impairment
(52). In light of the literature, post hoc we identified the
common SNPs reported in the early studies (49,50,52) to be asso-
ciated with the risk for ASD or language impairment (Table 5)
and evaluated their association to ASD and age-at-first-word
and -phrase for all three inheritance patterns. Of the three SNPs
reported in the literature, one (rs2710102) shows very modest as-
sociation with the risk for ASD. For the language outcomes,
rs1718101 shows modest, significant association with
age-at-first-phrase, acting either additively or dominantly but
not recessively; rs17236239 shows modest association with
age-at-first-phrase under a recessive model (Table 5).
In our previous study, we highlighted association with SNPs
within MACROD2. The most highly associated MACROD2
SNP from primary Stage 1 analyses, rs4141463 (P-value ¼
2.40 × 1028; OR ¼ 0.65), obtained by analyses of subjects
with a strict diagnosis of autism and of European ancestry,
showed little if any signal in the Stage 2 sample (P-value ¼
0.206, OR ¼ 0.91). Thus, for the mega-analysis reported
here, the association is less compelling (P-value ¼ 1.2 ×
1026; OR ¼ 0.77) than previously reported (21). Within this
large gene three SNPs show substantial but still non-
significant over-transmission of specific alleles from mothers
(Table 3). The region encompassed by these three SNPs cap-
tures the 3′ region of a putative antisense RNA, specifically
CR596518, and one SNP falls in its translated region
(rs14135). Because antisense RNA can play a role in the
mechanics of imprinting (53), this observation is of some
note. Nonetheless, without additional biological or statistical
evidence, the result is unconvincing. Thus, whether SNPs in
MACROD2 or in its intra-genic antisense RNA genes play a
role in the risk for ASD remains an open question. If they
do, however, there can now be little doubt that their effect
size is modest on the basis of our results and others (24).
That no individual common variants are significantly asso-
ciated with the risk for ASD in our data was anticipated by
earlier analyses (28), based on results from three GWAS
studies and statistical theory regarding the relationships
among sample size, effect size and power. These analyses pre-
dicted that few if any common variants have an impact on risk
exceeding 1.2 (or below its inverse). Our results from .2700
trios, together with the results from other published GWAS
(22,23,34), bear out this prediction. The analyses laid out in
Devlin et al. (28) cannot be precise when predicting the
number of loci with common variants of modest impact on
risk (0.8, risk ,1.2); the modelling is consistent with a
range of loci from zero to many thousands.
Figure 1. Additive genetic variance at marker (VM) explained by the Stage 1-derived allele score in Stage 2 probands and pseudo controls for a given ancestry
and diagnostic classification. Significant association of the allele score denoted by (∗P , 0.05, ∗∗P , 0.01, ∗∗∗P, 0.001). Note that the number of predictors, at
a given threshold, is roughly the threshold times the number of SNPs meeting quality control criteria (947 233).
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Secondary approaches are being developed and applied to
GWAS data to explore further the role of common variation
within ASD. The AGP and others have applied diverse analyt-
ic approaches to determine whether there is evidence of
enriched association in specific genes and groups of genes
(54–57), whether there are regions of extended homozygosity
within affected individuals that may implicate regions har-
bouring putatively recessive alleles (58) or to explore more
discrete trait-based phenotypes within genome-wide data
(59–61). To seek evidence for or against common variants
having this modest impact on risk, we approached the
problem by constructing an allele score, based on the transmis-
sion properties of SNP alleles in Stage 1 data, and asking
whether these composite scores from putative risk alleles
could predict case and pseudo-control status in Stage 2. In
other words, do common variants over-transmitted in Stage 1
also tend to be observed in Stage 2? If so, this may provide evi-
dence that common variants affect the risk for ASD. Moreover,
when combined with the published GWAS results and the
theory in Devlin et al. (28), they illuminate how common var-
iants affect risk: individually they have very small effect, but en
masse they exert a detectable impact. This logical circle is now
closed. We find that allele scores derived in Stage 1 do indeed
predict case and pseudo-control status in Stage 2, making the
case that common variants affect the risk for ASD. The
score cannot account for much of the variance, ,1%, and
only about a third of that recently explained for schizophrenia
(30). Thus, while the existence of common variants affecting
the risk of ASD is almost assured, their individual effects
are modest and their collective effects could be smaller than
that for rare variation.
On the other hand, complementing the allele-score analysis,
gene-set enrichment and related analyses for AGP and other
ASD data sets have found significant evidence for common
variants affecting risk (54–57), suggesting that common var-
iants account for a non-trivial proportion of risk and that
many true positive associations of small effect could be
buried in the noise of stochastic variation. Qualitatively,
recent studies of rare variants also find it challenging to distin-
guish risk variation from the background stochastic noise (12–
15). Given these challenges, it is reasonable to conjecture that
even if all of the samples analysed here were also sequenced at
the whole genome level, it would still be impossible to discern
how much risk accrues from common versus rare variation, at
least from current knowledge. Thus a precise estimate of the
relative contribution of rare and common variation to risk
will require further studies.
MATERIALS AND METHODS
Clinical evaluation
Participants in this AGP study were recruited at centres in
North America and Europe. Subjects with known karyotypic
Table 5. Family-based quantitative trait analysis at previously implicated CNTNAP2 SNPs for age at first word and phrase for ASD subjects and three models of
inheritance, as well as qualitative analysis of ASD risk
SNP Genotype
(riska)
Chr Position Minor Major MAF Z(ADD) p(ADD) Z(DOM) p(DOM) Z(REC) p(REC)
Age-at-first-word
rs1718101f R(A) 7 145753721 A G 0.054 21.78 0.074 21.51 0.130 21.72 0.086
rs7794745g W(T)e 7 146120539 T A 0.345 1.09 0.276 0.45 0.654 1.36 0.173
rs2710102h R(G) 7 147205323 A G 0.483 1.49 0.136 0.53 0.595 1.69 0.091
rs17236239i R(G) 7 147213238 G A 0.344 20.81 0.419 21.14 0.253 0.25 0.805
Age-at-first-phrase
rs1718101f R(A) 7 145753721 A G 0.054 22.40 0.017c 22.42 0.015c 20.32 0.752
rs7794745g W(T)e 7 146120539 T A 0.345 0.12 0.907 0.07 0.945 0.12 0.909
rs2710102h R(G) 7 147205323 A G 0.483 1.08 0.279 0.02 0.984 1.70 0.089
rs17236239i R(G) 7 147213238 G A 0.344 0.37 0.711 21.17 0.241 2.37 0.018b
SNP Genotype
(riska)
Chr Position Minor Major MAF OR (95%CI) p(ADD)
All ASD
rs1718101f R(A) 7 145753721 A G 0.054 1.25 (1.06–1.49) 0.010b
rs7794745g W(T)e 7 146120539 T A 0.345 0.90 (0.79–1.03) 0.120
rs2710102h R(G) 7 147205323 A G 0.483 1.08 (1.00–1.16) 0.045b
rs17236239i R(G) 7 147213238 G A 0.344 0.95 (0.88–1.03) 0.200
European, higher IQ
rs1718101f R(A) 7 145753721 A G 0.054 2.13 (1.63–2.80) 7.78E-9d
rs7794745g W(T)e 7 146120539 T A 0.345 0.86 (0.71–1.04) 0.116
rs2710102h R(G) 7 147205323 A G 0.483 1.02 (0.91–1.15) 0.740
rs17236239i R(G) 7 147213238 G A 0.344 1.05 (0.93–1.19) 0.410
aRisk allele reported in initial association study.
bAssociation effect observed in same direction as initial association.
cAssociation effect observed in opposite direction as initial association.
dAssociation is initial study.
eRisk allele for ambiguous SNP (A/T) defined according to minor allele frequency.
Studies are fthis study; gArking et al. (50); hAlarcon et al. (49); iVernes et al. (52).
P-values, 0.1 are italicized, those ,0.05 also in bold.
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abnormalities and fragile X mutations were typically
excluded. Likely affected individuals were assessed using
the Autism Diagnostic Interview-Revised (62) and Autism
Diagnostic Observation Schedule (63). Cognitive functioning
was established for the majority of subjects using a range of
cognitive measures from which a categorical classification of
intellectual capacity was derived for the analyses, as described
below and elsewhere (21).
Genotyping
The Stage 1 sample was genotyped using the Illumina Infi-
nium 1M-single SNP microarray; the Stage 2 sample was gen-
otyped on either the Illumina Infinium 1M-single or the
Illumina 1M-duo microarray. All quality control (QC) proce-
dures were consistent across data sets and are described else-
where (21). For subjects inferred to be of European ancestry,
markers showing Fst .0.02 across recruitment sites were
excluded from analyses. A total of 947 233 SNPs passed QC
for the combined data sets.
Population structure
Ancestry for both Stage 1 and Stage 2 samples was estimated
by using 5176 SNPs, which had a genotype completion rate of
≥99.9%, and a minor allele frequency MAF ≥ 0.05 and were
separated by at least 500 kb. The initial dacGem (33) analysis
identified three dimensions of ancestry and separated the data
into five ancestry groups (Supplementary Material, Fig. S1).
Groups A through C, illustrated in Supplementary Material,
Figure S1, delineate 1285, 771 and 486 families of European
ancestry as determined by the representation of European re-
cruitment sites. All other families were assigned to be
non-European for purposes of association analysis (described
below). By using genotypes from the same panel of 5176
SNPs, we searched the data set for duplicate samples
between Stages 1 and 2, as well as within the Stages, and
found none.
Phenotype treatment
As described in Anney et al. (21), our primary analyses
grouped families into two nested diagnostic classes: strict, in
which affected individuals met both ADI-R and ADOS criteria
for autism; and spectrum, combining individuals meeting strict
criteria with individuals with a broader ASD diagnosis as
determined by responses to the ADI-R and ADOS. As
described above, we also grouped individuals on the basis of
ancestry. To evaluate the effect of transmitted alleles on the
risk of ASD, the primary analyses assume an additive model
and evaluated four overlapping data sets: two levels of diagno-
sis (spectrum versus strict diagnosis) by two levels of ancestry
(all ancestries versus European ancestry).
Secondary analyses (Supplementary Material, Fig. S2) were
also performed based on parent-of-origin, verbal/ non-verbal
status, IQ, age-at-first-words and age-at-first-phrases. The
parent-of-origin analysis treated paternal- and maternal-
specific transmissions separately for both strict and spectrum
diagnostic classes. Stratification by verbal/non-verbal status
as described in Liu et al. (64) was conducted in the total
sample. IQ-based analyses included data from subjects
whose IQ .80 (higher-IQ) and those with 25, IQ ,70
(lower-IQ). IQ categorization was determined using available
measures of verbal, non-verbal (performance) and full-scale
IQ assessments. A score .80 for any of these three measures
resulted in classification in the higher IQ group; otherwise,
individuals classified into the lower IQ group had IQ estimates
on at least two measures in the range 25–70. The age-at-first
word and the age-at-first-phrase were analysed as quantitative
variables (distributions shown in Supplementary Material,
Figs S8 and 9).
Genetic association analysis
Association analyses were performed as described elsewhere
(20). Briefly, family-based analyses were performed using
FBAT (65) and an in-house programme written for family-
based association (66) that implements methods described by
Cordell et al. (67). For parent-of-origin analyses, only the
latter was used. A summary of the sample size for analyses in-
volving Stage 2 and both Stages is given in Table 1.
Allele score analysis
Four allele scores were defined based on the GWA signals
from the four primary association analyses from Stage 1
described above. For each SNP, the risk allele was defined
as the over-transmitted allele. The SNP-specific component
of the score was calculated as the dosage of the allele multi-
plied by the corresponding log of the odds ratio, and was com-
puted for all autosomal SNPs. The individual-specific score
was calculated by summing over the SNP-specific component
values without mean imputation for missing data, using
PLINK version 1.07 (68). Ten scores were created for each in-
dividual using association thresholds of the P-value:
,0.00001, ,0.0001, ,0.001, ,0.01, ,0.05, ,0.1, ,0.2,
,0.3, ,0.4, ,0.5). The allele-score approach requires con-
trols as well as cases; to account for the family-based
design, we generated a pseudo control from the untransmitted
parental alleles using PLINK v1.07. For any particular SNP,
‘pseudo control’ is the term used for the three genotypes
that could have been formed by the parental alleles, but
were not; i.e. if parents have genotypes a1a2 and a3a4, and
their offspring is a1a3, then the pseudo controls are a1a4,
a2a3 and a2a4. These controls form the foundation for likeli-
hood calculations for family-based association analysis.
Logistic regression of Stage 2 case status on mean score was
performed, with covariates being the number of non-missing
genotypes for all SNPs used to calculate the score and four
dimensions of ancestry defined using PLINK v1.07. An ap-
proximation of the additive genetic variance explained by
the observed markers was calculated using the difference in
the Nagelkerke’s pseudo R-squared from a model including
the score and covariates versus a model including only the
covariates. Empirical significance of these findings was esti-
mated based on 1000 permutations through case–control ran-
domization within each data set.
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SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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